As master switches for a number of processes that are important to cell growth, and, with mTOR and Akt, part of the network that integrates nutritional status information with growth decisions, PI3 kinase inhibitors have "enormous promise attached to them" as cancer treatments, Dario Altieri told BioWorld Today.